Pharmacological inhibition of lipolysis prevents adverse metabolic outcomes during glucocorticoid administration

Highlights • Cort induces tissue-level substrate overload via mobilization of endogenous fuels. • Inhibiting lipolysis protects against glucocorticoid-induced iatrogenic diabetes. • Lipolysis primarily impacts metabolite alterations in muscle during Cort therapy. • Lipolysis accounts for a third of the genomic changes in liver during Cort therapy.